EMA Authorised: Zarzio (filgrastim) — Sandoz GmbH

View source ↗

Summary

The EMA authorised Zarzio, a filgrastim biosimilar from Sandoz GmbH, for use in hematopoietic stem cell transplantation and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Neutropenia
• Hematopoietic Stem Cell Transplantation
• Neutropenia

Drugs mentioned

• Zarzio® (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Sandoz GmbH. Decision date: 20/03/2025